LEADER 04310oam 2201249zu 450 001 9910698235503321 005 20231122000327.0 035 $a(CKB)3450000000002075 035 $a(SSID)ssj0000622399 035 $a(PQKBManifestationID)11383848 035 $a(PQKBTitleCode)TC0000622399 035 $a(PQKBWorkID)10642367 035 $a(PQKB)22010915 035 $a(WaSeSS)Ind00030679 035 $a(OCoLC)77638732 035 $a(EXLCZ)993450000000002075 100 $a20160829d2007 uy 101 0 $aeng 135 $aur||||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aTesting for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs 210 31$a[Place of publication not identified]$cAHRQ$d2007 215 $a1 online resource 225 0 $aEvidence report/technology assessment Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs) 300 $aBibliographic Level Mode of Issuance: Monograph 320 $aIncludes bibliographical references. 410 0$aEvidence report/technology assessment ;$vno. 146. 410 0$aAHRQ publication ;$vno. 07-E002. 606 $aSerotonin uptake inhibitors$xChemotherapy 606 $aCytochrome P-450 606 $aDepression, Mental 606 $aPharmacogenetics 606 $aGenetic Variation 606 $aDepressive Disorder 606 $aSerotonin Agents 606 $aAge Groups 606 $aNeurotransmitter Uptake Inhibitors 606 $aCytochromes 606 $aMixed Function Oxygenases 606 $aHemeproteins 606 $aGenetic Phenomena 606 $aMood Disorders 606 $aPersons 606 $aNeurotransmitter Agents 606 $aOxygenases 606 $aEnzymes and Coenzymes 606 $aProteins 606 $aMolecular Mechanisms of Pharmacological Action 606 $aPhysiological Effects of Drugs 606 $aOxidoreductases 606 $aMental Disorders 606 $aPharmacologic Actions 606 $aAmino Acids, Peptides, and Proteins 606 $aEnzymes 606 $aChemical Actions and Uses 606 $aPolymorphism, Genetic 606 $aCytochrome P-450 Enzyme System 606 $aAdult 606 $aDepressive Disorder, Major 606 $aSerotonin Uptake Inhibitors 606 $aHealth & Biological Sciences$2HILCC 606 $aPharmacy, Therapeutics, & Pharmacology$2HILCC 615 0$aSerotonin uptake inhibitors$xChemotherapy 615 0$aCytochrome P-450 615 0$aDepression, Mental 615 0$aPharmacogenetics 615 2$aGenetic Variation 615 2$aDepressive Disorder 615 2$aSerotonin Agents 615 2$aAge Groups 615 2$aNeurotransmitter Uptake Inhibitors 615 2$aCytochromes 615 2$aMixed Function Oxygenases 615 2$aHemeproteins 615 2$aGenetic Phenomena 615 2$aMood Disorders 615 2$aPersons 615 2$aNeurotransmitter Agents 615 2$aOxygenases 615 2$aEnzymes and Coenzymes 615 2$aProteins 615 2$aMolecular Mechanisms of Pharmacological Action 615 2$aPhysiological Effects of Drugs 615 2$aOxidoreductases 615 2$aMental Disorders 615 2$aPharmacologic Actions 615 2$aAmino Acids, Peptides, and Proteins 615 2$aEnzymes 615 2$aChemical Actions and Uses 615 2$aPolymorphism, Genetic 615 2$aCytochrome P-450 Enzyme System 615 2$aAdult 615 2$aDepressive Disorder, Major 615 2$aSerotonin Uptake Inhibitors 615 7$aHealth & Biological Sciences 615 7$aPharmacy, Therapeutics, & Pharmacology 676 $a615/.78 702 $aMatchar$b David B 712 02$aUnited States Agency for Healthcare Research and Quality 712 02$aDuke University Evidence-based Practice Center 801 0$bPQKB 906 $aBOOK 912 $a9910698235503321 996 $aTesting for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs$93140792 997 $aUNINA